Compounds > 2',3'-didehydro-2',3'-dideoxyuridine
Page last updated: 2024-12-06

2',3'-didehydro-2',3'-dideoxyuridine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2',3'-didehydro-2',3'-dideoxyuridine (ddU) is a nucleoside analog that inhibits DNA polymerase. It is a potent antiviral agent, particularly against the human immunodeficiency virus (HIV). ddU is a chain terminator, meaning that it prevents the elongation of DNA strands by DNA polymerase. The mechanism of action of ddU is based on its incorporation into the growing DNA chain by DNA polymerase. Due to the lack of a 3'-hydroxyl group, ddU cannot form a phosphodiester bond with the next nucleotide, leading to chain termination. ddU is an effective antiviral agent for the treatment of HIV infection, and its synthesis and biological activity have been extensively studied. It is often used in combination with other antiviral drugs to combat HIV infection and resistance. The study of ddU is important for understanding the mechanisms of DNA replication and for developing new antiviral drugs.'

Cross-References

ID SourceID
PubMed CID65159
CHEMBL ID89637
SCHEMBL ID543443
MeSH IDM0164122

Synonyms (21)

Synonym
CHEMBL89637 ,
ddeurd
d4u ,
1-[(2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl]pyrimidine-2,4-dione
uridine, 2',3'-didehydro-2',3'-dideoxy-
5974-93-6
2',3'-dideoxyuridinene
1-((2r,5s)-5-(hydroxymethyl)-2,5-dihydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione
bdbm50013115
1-(5-hydroxymethyl-2,5-dihydro-furan-2-yl)-1h-pyrimidine-2,4-dione (ddeurd)
2',3'-dideoxy-2',3'-didehydrouridine
2,4(1h,3h)-pyrimidinedione, 1-(2,5-dihydro-5-(hydroxymethyl)-2-furanyl)-, (2r-cis)-
2',3'-didehydro-2',3'-dideoxyuridine
SCHEMBL543443
NZXWQUCGACTHLK-POYBYMJQSA-N
AC-24683
CS-0100830
DTXSID50208453
AKOS025401704
F12170
HY-W048512
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thymidine kinase, cytosolicHomo sapiens (human)Ki445.00000.09001.52137.0000AID210879
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (10)

Processvia Protein(s)Taxonomy
nucleobase-containing compound metabolic processThymidine kinase, cytosolicHomo sapiens (human)
deoxyribonucleoside monophosphate biosynthetic processThymidine kinase, cytosolicHomo sapiens (human)
thymidine metabolic processThymidine kinase, cytosolicHomo sapiens (human)
thymidine biosynthetic processThymidine kinase, cytosolicHomo sapiens (human)
protein homotetramerizationThymidine kinase, cytosolicHomo sapiens (human)
DNA synthesis involved in mitotic DNA replicationThymidine kinase, cytosolicHomo sapiens (human)
nucleobase-containing compound metabolic processDeoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrialHomo sapiens (human)
dUMP biosynthetic processDeoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrialHomo sapiens (human)
dTMP biosynthetic processDeoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrialHomo sapiens (human)
DNA replicationDeoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrialHomo sapiens (human)
dUTP catabolic processDeoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
thymidine kinase activityThymidine kinase, cytosolicHomo sapiens (human)
protein bindingThymidine kinase, cytosolicHomo sapiens (human)
ATP bindingThymidine kinase, cytosolicHomo sapiens (human)
zinc ion bindingThymidine kinase, cytosolicHomo sapiens (human)
identical protein bindingThymidine kinase, cytosolicHomo sapiens (human)
RNA bindingDeoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrialHomo sapiens (human)
dUTP diphosphatase activityDeoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrialHomo sapiens (human)
protein bindingDeoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrialHomo sapiens (human)
magnesium ion bindingDeoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
nucleusThymidine kinase, cytosolicHomo sapiens (human)
cytosolThymidine kinase, cytosolicHomo sapiens (human)
nucleusDeoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrialHomo sapiens (human)
nucleoplasmDeoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrialHomo sapiens (human)
mitochondrionDeoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrialHomo sapiens (human)
extracellular exosomeDeoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrialHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (31)

Assay IDTitleYearJournalArticle
AID299251Inhibition of HIV1-induced cytopathogenicity in CEM/0 cells2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Design, synthesis, and anti-HIV activity of 2',3'-didehydro-2',3'-dideoxyuridine (d4U), 2',3'-dideoxyuridine (ddU) phosphoramidate 'ProTide' derivatives.
AID254408Inhibitory constant against Leishmania major deoxyuridine 5'-triphosphate nucleotidohydrolase2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target.
AID255974In vitro cytotoxicity against rat skeletal myoblasts (L-6 cells) after 72 hours; nd=not determined2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target.
AID255964In vitro inhibitory activity against Plasmodium falciparum as [3H]hypoxanthine (50 uL) incorporation at 37C2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target.
AID106768Cytotoxic dose required to reduce the viability of normal uninfected MT-4 cells by 50%1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and anti-HIV evaluation of 2',3'-dideoxyribo-5-chloropyrimidine analogues: reduced toxicity of 5-chlorinated 2',3'-dideoxynucleosides.
AID105766Toxicity was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 5 uM concentration1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
AID105750Protection was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 0.2 uM concentration1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
AID254455Inhibitory constant against human deoxyuridine 5'-triphosphate nucleotidohydrolase expressed in Escherichia coli BL21 (DE3) cells2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target.
AID154966Antiviral activity against HIV I strain (LAV) in human peripheral blood mononuclear (PBM) cells; Range is 68.3 - 79.91989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Structure-activity relationships of pyrimidine nucleosides as antiviral agents for human immunodeficiency virus type 1 in peripheral blood mononuclear cells.
AID152642Cytotoxic effect in uninfected human peripheral blood mononuclear (PBM) cells1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
Structure-activity relationships of pyrimidine nucleosides as antiviral agents for human immunodeficiency virus type 1 in peripheral blood mononuclear cells.
AID255969Inhibitory constant against Trypanosoma brucei rhodesiense upon incubation with the compound at 37 degrees C under a 5% CO2 atmosphere for 72 hours2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target.
AID105756Protection was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 5 uM concentration.1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
AID255973In vitro growth inhibitory activity against Trypanosoma cruzi in rat L-6 cells upon incubation at 37 degrees C in 5% CO2 atmosphere for 4 days2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target.
AID299252Inhibition of HIV2-induced cytopathogenicity in CEM/0 cells2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Design, synthesis, and anti-HIV activity of 2',3'-didehydro-2',3'-dideoxyuridine (d4U), 2',3'-dideoxyuridine (ddU) phosphoramidate 'ProTide' derivatives.
AID125177In vitro inhibitory activity against Moloney murine leukemia virus (M-MULV) replication, a mammalian T-lymphotropic retrovirus1987Journal of medicinal chemistry, Feb, Volume: 30, Issue:2
Synthesis and antiviral activity of various 3'-azido, 3'-amino, 2',3'-unsaturated, and 2',3'-dideoxy analogues of pyrimidine deoxyribonucleosides against retroviruses.
AID234204Therapeutic index (Ratio = ID50/ED50).1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
AID105764Toxicity was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 125 uM concentration1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
AID515879Antimalarial activity against Plasmodium falciparum 3D7 at 100 uM by SYBR green assay2010Bioorganic & medicinal chemistry, Oct-15, Volume: 18, Issue:20
Potential application of thymidylate kinase in nucleoside analogue activation in Plasmodium falciparum.
AID254490Inhibitory constant against Plasmodium falciparum deoxyuridine 5'-triphosphate nucleotidohydrolase expressed in Escherichia coli BL21 (DE3) cells2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target.
AID32065Protection of ATH8 cells against the cytopathic effect of HIV.1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
AID20871Partition coefficient (P) in 1-octanol and 0.1 M Na3PO4 at pH 71990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and in vitro evaluation of some modified 4-thiopyrimidine nucleosides for prevention or reversal of AIDS-associated neurological disorders.
AID255979In vitro growth inhibitory activity against Leishmania donovani amastigotes upon incubation with the compound at 37 degrees C under a 5% CO2 atmosphere for 96 hours; nd is not determined 2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target.
AID105747Protection was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 0.008 uM concentration.1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
AID299253Cytotoxicity against CEM/0 cells2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Design, synthesis, and anti-HIV activity of 2',3'-didehydro-2',3'-dideoxyuridine (d4U), 2',3'-dideoxyuridine (ddU) phosphoramidate 'ProTide' derivatives.
AID105762Toxicity was determined by evaluation of cluster morphology and reclustering properties in mock infected MT-4 cells at 0.2 uM concentration1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
AID235704Selectivity index of CD50 to ED50 of MT-4 cells1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and anti-HIV evaluation of 2',3'-dideoxyribo-5-chloropyrimidine analogues: reduced toxicity of 5-chlorinated 2',3'-dideoxynucleosides.
AID254568Selectivity index for Plasmodium falciparum deoxyuridine 5'-triphosphate nucleotidohydrolase defined as (Ki Human)/(Ki Plasmodium falciparum)2005Journal of medicinal chemistry, Sep-22, Volume: 48, Issue:19
Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target.
AID515880Antimalarial activity against Plasmodium falciparum 3D7 after 48 hrs by SYBR green assay2010Bioorganic & medicinal chemistry, Oct-15, Volume: 18, Issue:20
Potential application of thymidylate kinase in nucleoside analogue activation in Plasmodium falciparum.
AID32066Required dose to reduce viability of normal uninfected ATH8 cells.1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
3'-substituted 2',3'-dideoxynucleoside analogues as potential anti-HIV (HTLV-III/LAV) agents.
AID104310Effective dose achieving 50% protection of MT-4 cells against the cytopathic effect of HIV1990Journal of medicinal chemistry, Jun, Volume: 33, Issue:6
Synthesis and anti-HIV evaluation of 2',3'-dideoxyribo-5-chloropyrimidine analogues: reduced toxicity of 5-chlorinated 2',3'-dideoxynucleosides.
AID210879Inhibitory affect against rabbit thymus thymidine kinase1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and in vitro evaluation of some modified 4-thiopyrimidine nucleosides for prevention or reversal of AIDS-associated neurological disorders.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (37.50)18.7374
1990's2 (12.50)18.2507
2000's5 (31.25)29.6817
2010's3 (18.75)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.67

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.67 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.67)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
thymidine
[no description available]		2.3720pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite
cytarabine
[no description available]		1.9710beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside		antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent
thymidine monophosphate
Thymidine Monophosphate: 5-Thymidylic acid. A thymine nucleotide containing one phosphate group esterified to the deoxyribose moiety.. dTMP : The neutral species of thymidine 5'-monophosphate (2'-deoxythymidine 5'-monophosphate).		2.0310thymidine 5'-monophosphatefundamental metabolite
deoxycytidine
[no description available]		2.3720pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
2'-deoxyadenosine
2'-deoxyformycin A: RN not in Chemline 9/85; RN and structure given in first source		1.9710purine 2'-deoxyribonucleoside;
purines 2'-deoxy-D-ribonucleoside		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
stavudine
Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase		3.4880dihydrofuran;
nucleoside analogue;
organic molecular entity		antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
dideoxyadenosine
Dideoxyadenosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is an inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal side effect is nephrotoxicity. In vivo, dideoxyadenosine is rapidly metabolized to DIDANOSINE (ddI) by enzymatic deamination; ddI is then converted to dideoxyinosine monophosphate and ultimately to dideoxyadenosine triphosphate, the putative active metabolite.		2.3720adenosines;
purine 2',3'-dideoxyribonucleoside		EC 3.5.4.4 (adenosine deaminase) inhibitor;
EC 4.6.1.1 (adenylate cyclase) inhibitor
zalcitabine
Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.		3.3770pyrimidine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
alovudine
[no description available]		1.9710pyrimidine 2',3'-dideoxyribonucleoside
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		3.4880azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
3'-azido-2',3'-dideoxyuridine
[no description available]		2.6630
2',3'-dideoxycytidinene
2',3'-dideoxycytidinene: 2',3'-unsaturated derivative of 2',3'-dideoxycytidine; potent inhibitor of HTLV-III in vitro; structure given in first source		3.2360
2'3'-didehydro-2'3'-dideoxyadenosine
2'3'-didehydro-2'3'-dideoxyadenosine: structure given in first source		1.9710
3'-azido-2',3'-dideoxy-5-bromouridine
3'-azido-2',3'-dideoxy-5-bromouridine: a potent, selective inhibitor of HIV replication; a weak competitive inhibitor of thymidylate kinase		2.3720
3'-azido-2',3'-dideoxy-5-methylcytidine
3'-azido-2',3'-dideoxy-5-methylcytidine: inhibits reproduction of AIDS virus in cultured cells		2.6630
phosphoramidic acid
phosphoramidic acid: urease inhibitor; RN given refers to parent cpd; structure; do not confuse with phosphoramidites, which are organophosphorus compounds		2.4420phosphoric acid derivative
2',3'-dideoxythymidine
[no description available]		2.6630
2',3'-dideoxyuridine
[no description available]		8.0950pyrimidine 2',3'-dideoxyribonucleoside
5'-amino-2',5'-dideoxythymidine
5'-amino-5'-deoxythymidine: RN given refers to parent cpd		2.3720
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		2.05101,2,3-triazole
3'-amino-2',3'-dideoxythymidine
[no description available]		2.3720
3'-amino-2',3'-dideoxyuridine
3'-amino-2',3'-dideoxyuridine: structure given in first source; a major metabolite of the antiviral agent, 3'-azido-2',3'-dideoxyuridine		1.9710
3'-fluoro-2',3'-dideoxyuridine
[no description available]		2.420
3'-azido-2',3'-dideoxyadenosine
[no description available]		1.9710
3'-azido-2',3'-dideoxycytidine
[no description available]		2.6630
raluridine
raluridine: inhibitor of HIV; structure given in first source		1.9710
5-bromo-2',3'-dideoxyuridine
5-bromo-2',3'-dideoxyuridine: structure given in first source		1.9710
pyrophosphate
Diphosphates: Inorganic salts of phosphoric acid that contain two phosphate groups.		2.1110diphosphate ion
trovirdine
trovirdine: HIV-1 reverse transcriptase inhibitor		2.0110
deoxy-4-thiothymidine
4-thiothymidine: structure in first source		1.9710
3'-azido-2',3'-dideoxyuridine
3'-azido-2',3'-dideoxyuridine: structure given in first source		1.9710
didanosine
Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.		1.9710purine 2',3'-dideoxyribonucleosideantimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor
3'-azido-2',3'-dideoxyguanosine
[no description available]		2.0510
ConditionIndicatedRelationship StrengthStudiesTrials
Acquired-Immune Deficiency Syndrome Dementia Complex
[description not available]		01.9710
HIV
Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.		08.2360
AIDS Dementia Complex
A neurologic condition associated with the ACQUIRED IMMUNODEFICIENCY SYNDROME and characterized by impaired concentration and memory, slowness of hand movements, ATAXIA, incontinence, apathy, and gait difficulties associated with HIV-1 viral infection of the central nervous system. Pathologic examination of the brain reveals white matter rarefaction, perivascular infiltrates of lymphocytes, foamy macrophages, and multinucleated giant cells. (From Adams et al., Principles of Neurology, 6th ed, pp760-1; N Engl J Med, 1995 Apr 6;332(14):934-40)		01.9710
Acquired Immune Deficiency Syndrome
[description not available]		01.9710
Acquired Immunodeficiency Syndrome
An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993.		01.9710